The Motley Fool

A SWOT Analysis Of AstraZeneca Plc And GlaxoSmithKline plc

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

GlaxoSmithKline

With a market capitalisation of £80bn, GlaxoSmithKline (LSE: GSK)(NYSE: GSK.US) is the sixth largest company in the FTSE 100.

Strengths
GlaxoSmithKline operates in a highly regulated market. Many of its top products are protected by patents that prevent competition moving in and stealing sales. This gives the company an enormous stream of high-margin cashflows.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Weaknesses
Despite everything that GlaxoSmithKline has going for it, only modest earnings per share growth of 7.7% is forecast from the business in 2014. The current 2014 P/E of 13.3 could begin to look over-generous if growth expectations decline.

Opportunities
As economic growth in emerging markets lifts millions into the middle class, a whole new market opens up for GlaxoSmithKline. If Glaxo can get back on track in China, the company could have another decade of earnings growth ahead of it.

Threats
Back in July of this year, Glaxo shocked the markets when it admitted that some of its staff may have bribed Chinese doctors. Last month, Glaxo reported that the disruption to its business in China led to a 61% sales decline in the world’s most populated country.

AstraZeneca

AstraZeneca (LSE: AZN)(NYSE: AZN.US) is smaller than Glaxo, with a market capitalisation of ‘just’ £41bn.

Strengths
Like any successful pharmaceutical, the business underlying AstraZeneca is high margin with a high level of repeat purchase. One of the biggest attractions of the shares is the current large dividend yield, which is forecast to come in at 5.3% for this year.

Weaknesses
Market fears over AstraZeneca’s so-called ‘patent cliff’ have held back the shares in recent years. If AstraZeneca does not bring more patented drugs into its portfolio, earnings could decline fast.

Opportunities
AstraZeneca is aware of the risk to earnings and has been busy making acquisitions. The recent purchase of Pearl Therapeutics brings a portfolio of respiratory drugs into the AstraZeneca stable. Shareholders will hope that the company can continue to identify suitable bolt-ons and use its financial firepower to get the company growing again.

Threats
The biggest risk to the shares is that the company’s current strategy fails to deliver growth. This would see the shares re-rated significantly. Though not expensive today, it is not difficult to imagine a scenario where AstraZeneca shares end up 30% lower.

5 Stocks For Trying To Build Wealth After 50

Markets around the world are reeling from the coronavirus pandemic…

And with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.

But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be daunting prospect during such unprecedented times.

Fortunately, The Motley Fool is here to help: our UK Chief Investment Officer and his analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global lock-down…

You see, here at The Motley Fool we don’t believe “over-trading” is the right path to financial freedom in retirement; instead, we advocate buying and holding (for AT LEAST three to five years) 15 or more quality companies, with shareholder-focused management teams at the helm.

That’s why we’re sharing the names of all five of these companies in a special investing report that you can download today for FREE. If you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio, and that you can consider building a position in all five right away.

Click here to claim your free copy of this special investing report now!

> David does not own shares in any of the companies mentioned. The Motley Fool has recommended shares in GlaxoSmithKline.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.